FOXO4-DRI

Designed to make "zombie" cells finally die and leave healthy cells alone. Remarkable in mice, and never tested in a human.

Evidence: ELab & animal what's this?
Grade E. The mechanism is replicated in cells and mice. There is no human data of any kind.
Also known as: FOXO4 D-Retro-Inverso peptide
Class: Synthetic D-retro-inverso senolytic peptide. Frontier research compound.

The 30-second version

WhatA mirror-image peptide that frees p53 inside senescent cells, so they self-destruct.

Why people use itPeriodic clearance of senescent cells to restore tissue function with age.

The honest catchIt works by forcing cell death, and no human has ever been dosed in a trial.

What it is

With age, some damaged cells stop dividing but refuse to die. These senescent cells pile up and leak inflammatory signals (the SASP) that damage surrounding tissue. Clearing them reverses aspects of ageing in animals. FOXO4-DRI was built in 2017 to do exactly that. "D-retro-inverso" means it’s made from mirror-image amino acids in reverse order, so it resists breakdown but keeps its shape.

How it works

p53, the guardian, normally forces badly damaged cells into apoptosis, a controlled death.

The escape. Senescent cells overproduce FOXO4, which holds p53 hostage.

The key. FOXO4-DRI competes for that binding site and releases p53.

Death. Freed p53 triggers apoptosis, and the senescent cell dies.

Selective. Healthy cells don’t depend on that lock, so they’re spared.

The effect is temporary. Senescent cells build up again over roughly 8–12 weeks, which is why the research describes periodic clearance rather than continuous use.

What the research shows

In mice (Baar et al., Cell 2017): in naturally aged mice it improved physical activity, kidney function and fur density together, reduced senescence markers, helped recovery from chemotherapy toxicity, and counteracted ageing in a fast-ageing strain. The dose was 5 mg/kg into the abdomen three times a week¹. Independent replication: it selectively cleared senescent human cartilage cells², and in separate work it cleared senescent vessel cells and improved vascular ageing in mice through p53³. In people: nothing.

Exciting, replicated science. A compound that triggers cell death, dosed by extrapolating from mice, is a different category of risk.

Evidence at a glance

Use	Grade	Best evidence	Main gap	Read
Clears senescent cells	ELab & animal	Selective, replicated^1,2	Cells and mice	Real mechanism
Reverses signs of ageing	ELab & animal	Activity, kidney, fur improved¹	Mouse only	Striking
Vascular ageing	ELab & animal	Improved aortic ageing³	Preclinical	Supportive
Human safety and benefit	ELab & animal	None	Never tested	Unknown

Dosing: what has been reported

Not a recommendation. These figures describe what was studied or what circulates in practice, kept separate so you can see how solid each one is. Speak with a qualified clinician before acting on any of it.

Setting	Figure	Route	Grade
Published human	None. Mouse protocol: 5 mg/kg intraperitoneal ×3 weekly¹	—	—
Community pulse	~1 mg/day, 5 days on and 2 off, 2-week course, 2–3 times a year	Subcutaneous	D
Community, higher	2–10 mg (some to 25 mg) every other day, ~3 doses per cycle	Subcutaneous	D
Community, weekly	5–10 mg weekly or fortnightly over a 4–8-week cycle	Subcutaneous	D

The range, from under 1 mg to 25 mg per dose, shows that nobody knows the human dose. Cycles are spaced 3–6 months apart. The community rule is "clear first, rebuild after": regenerative peptides come after a cycle, not during it.

Preparing & storing

A common mix is 10 mg in 2 mL of bacteriostatic water (5 mg/mL; 1 mg = 20 units on a U-100 syringe). Store the powder frozen, refrigerate once mixed and use within about two weeks. Injection-site soreness is notably more common and longer-lasting than with most peptides, so inject slowly at room temperature and rotate sites widely.

Reported side effects

Injection-site soreness lasting several days, worse at higher doses
Mild fatigue, muscle soreness, nausea (anecdotal)
Real human side-effect profile: unknown

People who use it track a general health panel plus p16INK4a and SASP markers (IL-6, TNF-α, hs-CRP) before and after a cycle.

Who should avoid it

Active or past cancer. p53 and apoptosis are central to cancer biology.
Pregnancy and breastfeeding: avoid absolutely
Anyone on chemotherapy or other apoptosis-affecting drugs
Realistically, anyone unwilling to be an early human test

Regulatory status checked Oct 2026

Body	Status	Detail
FDA (US)	Not approved	Research compound.
EMA (EU)	Not approved	—
CDSCO (India)	Not approved	—
WADA	Not named	S0 could apply.

The NexGen read

Frontier science, frontier risk

FOXO4-DRI has one of the most elegant mechanisms in this guide and replicated mouse data. It also has no human dose, no human safety data, and it works by making cells die. If you are not a researcher, the right place for it is in your reading, not in a syringe.

References

Baar MP, Brandt RMC, Putavet DA, et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell. 2017;169(1):132–147. PMID 28340339
Senolytic peptide FOXO4-DRI selectively removes senescent cells from in vitro expanded human chondrocytes. 2021. PMC8116695
FOXO4-DRI regulates endothelial cell senescence via the p53 signaling pathway. PMC12852416